Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.
Vitruvian
Preventing Hernias Before They Happen

December 10, 2013
Mentor: Julie Cherrington
Team:
Cindy Chang, PhD
Hobart...
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.

Hernia (%)

100
80
60
40
20
0
saline

tissue sealant

low dose
MYOSEAL

high dose
...
Preventing hernias before they happen.
Business Model Canvas
Interviews

President of Paradigm Medical Consultants:
Medical insurers do want to keep cost down
but they have limited ab...
Interviews

Quotes from Surgeons

My patients don’t develop hernias after my
operations. The 10% incidence quoted in the
l...
Business Model Canvas

???
Interviews
Quote from Key Opinion Leader

With strong clinical data, I think most surgeons
would adopt hernia prevention. ...
Interview Partners
Partner Interviews
Myoseal Finance & Operations Timeline
Program
Pre-clinical
Formulation,
toxicology &
IND
enabling
studies

2014
1Q

2Q

20...
De-risk the Technology

Change to another
indication with the
same product

Alter the product
composition
Therapeutic Investment Readiness Level

Plausible exit
Cash to exit
Unit economics Validated
Reimbursement
Regulatory
Inte...
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Therapeutic Investment Readiness Level Plausible
Próxima SlideShare
Cargando en…5
×

Therapeutic Investment Readiness Level Plausible Vitruvian week 10 presentation

80.035 visualizaciones

Publicado el

Therapeutic Investment Readiness Level

Plausible exit
Cash to exit
Unit economics Validated
Reimbursement
Regulatory
Intellectual Property
Attractive solution & ID of MVP
Compelling clinical need + large mkt
Effective team?

  • Sé el primero en comentar

×